Xanthoma disseminatum

LAST UPDATED: Aug 02, 2021

Introduction

This is a rare non-familial disease, characterised by proliferation of non–Langerhans, histiocytic cells in which lipid deposition is a secondary event.

This chapter is set out as follows:


History

  • Mainly affects children and young adults
  • Males are more commonly affected than females

Clinical findings

Distribution

  • Face, trunk and proximal extremities, especially at flexural sites
  • Symmetrical distribution

Morphology

  • Yellow-brown papules, and nodules
  • Lesions become confluent, especially in the flexures, to form xanthomatous plaques, which may then become verrucous

Additional features

  • In 30% of cases the mucous membranes are affected, including from the lips to upper respiratory tract
  • Meningeal involvement is common, leading to diabetes insipidus in up to 40% of cases, seizures and growth retardation
  • Other organ involvement is much less common

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Management

  • Xanthoma disseminatum is self-limiting but may persist for many years or even decades
  • Depending on symptoms, further investigations and a multi-disciplinary team approach may be needed
  • Skin lesions may be disfiguring - treatment with a carbon dioxide laser can have good results

Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco